Relmada Therapeutics, Inc.

NASDAQ:RLMD

Biotechnology

Healthcare
$3.11 -0.97%

-$0.06 today

Market cap
$331.82M
Beta
0.39
P/E (TTM)
-9.6
EPS (TTM)
-$0.68
52W Low $0.52High $8.00

Volume 1.71M

Average 1.24M

Returns on capital

Relmada Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-66.3%

avg -107.9%

ROIC

-67.5%

avg -108.6%

ROA

-61.0%

avg -115.7%

Analysis

ROA is currently the strongest return metric at -61.0% versus its period average of -115.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Sergio Traversa

Chief Executive Officer & DirectorUSD 3.94M661.50M2.05%

Maged S. Shenouda

Chief Financial OfficerUSD 2.64M62——

Charles S. Ence

Chief Accounting & Compliance OfficerUSD 2.17M61——

Paul E. Kelly

Chief Operating Officer & DirectorUSD 1.96M69——

Andrew Cutler

Senior Clinical Development Advisor————

Bipin K. Dalmia

Chief Business Officer————

Raj S. Pruthi

Chief Medical Officer of Urology—59——

Richard Mangano

Consultant—76——

Gina DiGuglielmo

Vice President & Head of Clinical Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

6

$1.83M

Sells

0

$0.00

Net Transaction Value

+$1.83M

Net buying

Most Active

TRAVERSA SERGIO

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 10, 26

TRAVERSA SERGIO

Direct

Buy$410K
Sep 10, 26

Shenouda Maged

Direct

Buy$339.2K
Sep 9, 26

TRAVERSA SERGIO

Direct

Buy$418K
Sep 9, 26

Shenouda Maged

Direct

Buy$504.8K
Dec 15, 25

Shenouda Maged

Direct

Buy$48.1K
Dec 15, 25

TRAVERSA SERGIO

Direct

Buy$113.3K

Summary

Insiders reported 6 buys worth $1.83M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.83M. TRAVERSA SERGIO was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Relmada Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about RLMD's management, answered from reported figures.

Who manages RLMD?

Relmada Therapeutics, Inc. (RLMD) lists 9 active executives. The top listed executive is Andrew Cutler, Senior Clinical Development Advisor.

Are RLMD insiders buying or selling?

Recent insider activity shows net buying of $74.48M.